List of works - Franca Stivala

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

scientific article published on 21 February 2008

Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).

scientific article published on March 2008

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

scientific article published on 15 April 2010

Emerging MEK inhibitors.

scientific article published on June 2010

Emerging Raf inhibitors.

scientific article published on December 2009

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy

scientific article published on 15 May 2010

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

scientific article published on September 2011

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

scientific article published on July 2011

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

scientific article published on 23 May 2009

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

scientific article published on March 2011

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

scientific article

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

scientific article

Targeting prostate cancer based on signal transduction and cell cycle pathways.

scientific article published on 16 June 2008

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

scientific article published on 26 March 2007

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

scientific article published on 10 May 2010

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

scientific article

List of works by Franca Stivala

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

Emerging MEK inhibitors.

Emerging Raf inhibitors.

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.